Cannabis stocks mixed as investors parse FDA’s latest comments on CBD regulation

March 2, 2019

Read Article Join Our Mailing List

Save as PDF

Cannabis stocks were mixed on Friday, as investors and company executives continued to parse comments by the head of the U.S. Food and Drug Administration on the outlook for regulation of CBD.

FDA Commissioner Scott Gottlieb on Wednesday announced plans to hold the first public meetings on the matter in April and offered a few hints at his thinking on the issue. Many cannabis companies are planning to launch food, drink and cosmetics lines that contain CBD, a non-psychoactive ingredient in cannabis that is widely believed to have wellness properties, but which has not been subjected to the kind of research that has been conducted on THC, the plant’s psychoactive ingredient.

No aspect of this advertisement has been approved by the highest court in any state.

Results may vary depending on your particular facts and legal circumstances.

As the law continues to evolve on these matters, please note that this article is current as of date and time of publication and may not reflect subsequent developments. The content and interpretation of the issues addressed herein is subject to change. Cole Schotz P.C. disclaims any and all liability with respect to actions taken or not taken based on any or all of the contents of this publication to the fullest extent permitted by law. This is for general informational purposes and does not constitute legal advice or create an attorney-client relationship. Do not act or refrain from acting upon the information contained in this publication without obtaining legal, financial and tax advice. For further information, please do not hesitate to reach out to your firm contact or to any of the attorneys listed in this publication.